Theriva Biologics, Inc.
TOVXNYSE
$0.24
↑ +5.5%Jul 17 close · end-of-day
Price
1Y↓ -48.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$9.9M
Enterprise Value
-$4.5M
P/E
—
P/S
—
P/B
0.6
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
—
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
—
ROIC
-1775.9%
Debt / Equity
—
Net Cash
$14.4M
Return 1Y
-49.5%
Company profile
Synthetic Biologics, Inc. develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade intravenous beta-lactam antibiotics in gastrointestinal (GI) tract. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma.
- CEO
- Steven A. Shallcross
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Maryland
- Website
- therivabio.com
Earnings
TOVX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$300,000.00—
Diluted EPS-$0.05↓ -96.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$10.2M | -$14.3M | -$21.6M | -$21.4M | -$26.3M | -$24.1M |
| Net income | -$10.0M | -$14.3M | -$19.7M | -$18.3M | -$25.7M | -$23.7M |
| Diluted EPS | -$0.66 | -$1.90 | -$1.31 | -$28.48 | -$19.03 | -$2.08 |
| Operating cash flow | -$12.2M | -$12.9M | -$19.1M | -$19.0M | -$16.9M | -$16.7M |
| Free cash flow | -$12.2M | -$12.9M | -$19.2M | -$19.2M | -$16.9M | -$16.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $300,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$8.5M | -$7.9M | -$4.6M | -$4.4M | -$13.1M | -$4.4M | -$2.1M | -$2.1M |
| Net income | — | — | — | — | — | — | — | — |
| Diluted EPS | -$10.72 | -$6.81 | $6.03 | -$1.55 | -$1.93 | -$0.45 | $1.85 | -$0.05 |
| Operating cash flow | -$3.5M | -$3.9M | -$4.7M | -$4.8M | -$4.7M | -$4.3M | -$2.9M | -$2.5M |
| Free cash flow | — | -$3.9M | — | — | — | -$4.3M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | -709.0% |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.